Translate Bio Announces Oral Presentation of mRNA Therapeutics in Models of Metabolic Disorders at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
29 avr. 2019 08h45 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio Appoints Robert Plenge, M.D., Ph.D., to its Board of Directors
11 avr. 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., April 11, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio Appoints Richard Wooster as Chief Scientific Officer
08 avr. 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio Appoints Pasquale (Pat) Sacco as Senior Vice President of Technical Operations
01 avr. 2019 07h30 HE
|
Translate Bio, Inc.
-- New role expands Company’s manufacturing expertise to support pipeline of mRNA therapeutics in development for rare, genetic diseases -- LEXINGTON, Mass., April 01, 2019 (GLOBE NEWSWIRE) --...
Translate Bio Granted U.S. Patent Relating to Messenger RNA (mRNA) Delivery
26 mars 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Fourth Quarter and Full Year 2018 Financial Results and Reviews Recent Highlights
21 mars 2019 16h29 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Publication of Preclinical Data Demonstrating Efficacy of Systemic mRNA Delivery in Fabry Disease Model in the Journal Molecular Therapy
18 mars 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
14 févr. 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Expands Patent Portfolio with Newly Issued U.S. Patent Relating to Its Messenger RNA (mRNA) Therapeutics Platform (MRT™)
04 déc. 2018 09h15 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Third Quarter 2018 Financial Results and Reviews Recent Highlights
08 nov. 2018 16h21 HE
|
Translate Bio, Inc.
Continued progress with ongoing Phase 1/2 clinical trial in CF and towards IND submission for OTC Deficiency LEXINGTON, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a...